Fig. 2
From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer
Kaplan–Meier curves: biochemical progression-free survival in patients aged ≤ 70 and > 70 years (a), with synchronous oligometastatic disease, metachronous oligorecurrent disease or other (de-novo oligoprogressive, repeat oligometastatic or induced oligometastatic disease) (b), with or without concomitant ADT (c), with hormone-sensitive prostate cancer or castration-resistant prostate cancer (d)